10091 related articles for article (PubMed ID: 18616910)
1. [Establishment of B16-HLA-MAGE-3 melanoma cell line coexpressing HLA-A 0201/K(b) and MAGE-3 and its role in tumor vaccine evaluation].
Song SX; Yan CZ; Zheng L; You HY; Wang JX; Liu FY
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Jul; 24(7):679-82. PubMed ID: 18616910
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
3. [Establishment of mouse melanoma B16 cell lines co-expressing MAGE-1 and EGFP].
Chen GS; Ye J; Song HP; Zhang XM; Huang YY; Ma JH; Sui YF
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Mar; 20(2):212-4. PubMed ID: 15191728
[TBL] [Abstract][Full Text] [Related]
4. Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy.
Sypniewska RK; Hoflack L; Tarango M; Gauntt S; Leal BZ; Reddick RL; Gravekamp C
Breast Cancer Res Treat; 2005 May; 91(1):19-28. PubMed ID: 15868428
[TBL] [Abstract][Full Text] [Related]
5. A novel DNA vaccine constructed by heat shock protein 70 and melanoma antigen-encoding gene 3 against tumorigenesis.
Qu P; Ma JH; Zhang XM; Huang XJ; Yang XW; Yan-Fang S
Indian J Exp Biol; 2010 May; 48(5):436-43. PubMed ID: 20795360
[TBL] [Abstract][Full Text] [Related]
6. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
7. [Construction of human MAGE-3 DNA vaccine and its immune effects observed in vivo].
Liu XE; Sun XD; Wu JM
Sheng Wu Gong Cheng Xue Bao; 2004 Mar; 20(2):165-9. PubMed ID: 15969102
[TBL] [Abstract][Full Text] [Related]
8. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.
Godelaine D; Carrasco J; Brasseur F; Neyns B; Thielemans K; Boon T; Van Pel A
Cancer Immunol Immunother; 2007 Jun; 56(6):753-9. PubMed ID: 17096150
[TBL] [Abstract][Full Text] [Related]
9. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1.
Hanagiri T; van Baren N; Neyns B; Boon T; Coulie PG
Cancer Immunol Immunother; 2006 Feb; 55(2):178-84. PubMed ID: 16187089
[TBL] [Abstract][Full Text] [Related]
10. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
[TBL] [Abstract][Full Text] [Related]
11. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
[TBL] [Abstract][Full Text] [Related]
12. An HLA-A2 polyepitope vaccine for melanoma immunotherapy.
Mateo L; Gardner J; Chen Q; Schmidt C; Down M; Elliott SL; Pye SJ; Firat H; Lemonnier FA; Cebon J; Suhrbier A
J Immunol; 1999 Oct; 163(7):4058-63. PubMed ID: 10491010
[TBL] [Abstract][Full Text] [Related]
13. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.
Kazaks A; Balmaks R; Voronkova T; Ose V; Pumpens P
Biotechnol J; 2008 Nov; 3(11):1429-36. PubMed ID: 18956370
[TBL] [Abstract][Full Text] [Related]
14. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen.
Hoon DS; Yuzuki D; Hayashida M; Morton DL
J Immunol; 1995 Jan; 154(2):730-7. PubMed ID: 7814879
[TBL] [Abstract][Full Text] [Related]
15. Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma.
Vogel TU; Visan L; Ljutic B; Gajewska B; Caterini J; Salha D; Wen T; He L; Parrington M; Cao SX; McNeil B; Sandhu D; Scollard N; Zhang L; Bradley B; Tang M; Lovitt C; Oomen R; Dunn P; Tartaglia J; Berinstein NL
J Immunother; 2010 Oct; 33(8):743-58. PubMed ID: 20842062
[TBL] [Abstract][Full Text] [Related]
16. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
17. [Melanoma antigen-3 expression in human hepatocellular carcinoma].
Cai S; Zhao H; Leng X; Cheng J; Gong S; Peng J; Cong X; Wang Y; Rui J; Hui Y; Du R; Chen W
Zhonghua Wai Ke Za Zhi; 2000 Sep; 38(9):693-6. PubMed ID: 11832142
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo.
Ma JH; Sui YF; Ye J; Huang YY; Li ZS; Chen GS; Qu P; Song HP; Zhang XM
Cancer Immunol Immunother; 2005 Sep; 54(9):907-14. PubMed ID: 15756604
[TBL] [Abstract][Full Text] [Related]
19. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
20. Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants.
Lin J; Lin L; Thomas DG; Greenson JK; Giordano TJ; Robinson GS; Barve RA; Weishaar FA; Taylor JM; Orringer MB; Beer DG
Clin Cancer Res; 2004 Sep; 10(17):5708-16. PubMed ID: 15355897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
